aspirin and Lung Neoplasms studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

Excerpt	Relevance	Reference
"Regular aspirin use may decrease cancer risk by reducing chronic inflammation."	9.20	Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Chaturvedi, AK; Hildesheim, A; Katki, HA; Kemp, TJ; Lang Kuhs, KA; Loftfield, E; Pinto, LA; Purdue, MP; Safaeian, M; Shiels, MS; Trabert, B; Wentzensen, N, 2015)
"Clinical evidence recently suggests that the regular use of aspirin is associated with a lower risk of breast cancer metastasis, but mechanisms remain unclear."	8.12	Aspirin suppresses breast cancer metastasis to lung by targeting anoikis resistance. ( Chen, W; Dong, Z; Li, H; Xu, R; Yan, Y; Zhang, H; Zheng, X, 2022)
"In this study, we observed that low-dose aspirin use was associated with a lower risk of lung carcinoma and lung carcinoma-related mortality among COPD patients."	8.12	Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: A cohort study. ( Cheung, KS; Ip, MS; Li, HL; Li, X; Ren, QW; Tse, HF; Wong, PF; Wu, MZ; Yiu, KH; Yu, SY, 2022)
"The antiproliferative activity of the aspirin derivative [2-acetoxy-(2-propynyl)benzoate]hexacarbonyldicobalt (Co-ASS) and its analogue hexacarbonyl[μ-(2-ethylphenyl)methanol]dicobalt (Co-EPM) was investigated on malignant pleural mesothelioma (MPM) cell lines, having an epithelioid or a sarcomatoid phenotype."	7.79	The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells. ( Bonarrigo, I; Gabano, E; Gust, R; Osella, D; Ravera, M; Zanellato, I, 2013)
"A patient who had small cell lung cancer complicated by symmetrical peripheral gangrene, secondary to spontaneous platelet aggregation, improved dramatically after starting aspirin treatment."	7.68	Digital gangrene in small cell lung cancer: response to aspirin treatment. ( Arrowsmith, JE; Bevan, DH; Cummin, AR; Nanson, EM; Woodhead, MA, 1991)
"Systematic inflammation has been reported to contribute to cancer progression through various mechanisms; however, the exact mechanism is still the subject of research."	5.91	Inhibitory effect of aspirin on inflammation-induced lung metastasis of cancer cells associated with neutrophil infiltration. ( Fukuda, K; Hirahashi, J; Kawakubo, H; Kitagawa, Y; Kobayashi, R; Matsuda, S; Matsui, K; Nakamura, R; Nishimura, E; Okubo, K; Takeuchi, M, 2023)
" Animals were treated with a dosage regimen of aspirin which inhibited PES but had no effect on the cytochrome P-450-dependent oxidation of 7,8-dihydrodihydroxybenzo(a)pyrene."	5.27	Effect of aspirin and indomethacin on the formation of benzo(a)pyrene-induced pulmonary adenomas and DNA adducts in A/HeJ mice. ( Adriaenssens, PI; Anderson, MW; Boorman, GA; Eling, TE; Sivarajah, K, 1983)
"Regular aspirin use may decrease cancer risk by reducing chronic inflammation."	5.20	Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Chaturvedi, AK; Hildesheim, A; Katki, HA; Kemp, TJ; Lang Kuhs, KA; Loftfield, E; Pinto, LA; Purdue, MP; Safaeian, M; Shiels, MS; Trabert, B; Wentzensen, N, 2015)
"Evidence clearly shows a chemopreventive effect for aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer and probably other cancer types; however, data on the risk-benefit profile for cancer prevention are insufficient and no definitive recommendations can be made."	4.85	Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. ( Baron, JA; Brown, PH; Burn, J; Cuzick, J; Greenwald, P; Jankowski, J; La Vecchia, C; Meyskens, F; Otto, F; Senn, HJ; Thun, M, 2009)
"Only case-control studies and most of the prospective cohort studies showed a reduction of colorectal cancer incidence in regular aspirin users."	4.80	[Aspirin against cancer]. ( de Gramont, A; Mabro, M, 2000)
"Clinical evidence recently suggests that the regular use of aspirin is associated with a lower risk of breast cancer metastasis, but mechanisms remain unclear."	4.12	Aspirin suppresses breast cancer metastasis to lung by targeting anoikis resistance. ( Chen, W; Dong, Z; Li, H; Xu, R; Yan, Y; Zhang, H; Zheng, X, 2022)
"In this study, we observed that low-dose aspirin use was associated with a lower risk of lung carcinoma and lung carcinoma-related mortality among COPD patients."	4.12	Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: A cohort study. ( Cheung, KS; Ip, MS; Li, HL; Li, X; Ren, QW; Tse, HF; Wong, PF; Wu, MZ; Yiu, KH; Yu, SY, 2022)
"Acetylsalicylic acid (ASA, aspirin) is a medication widely used for primary and secondary prevention of cardiovascular diseases, which are the leading cause of morbidity and mortality worldwide."	3.91	Aspirin for patients undergoing major lung resections: hazardous or harmless?†. ( Messerschmidt, A; Schneider, T; Stamenovic, D, 2019)
"To investigate the association of aspirin use with risk of all-cause, any cancer, gastrointestinal (GI) cancer, and colorectal cancer (CRC) mortality among older adults and to perform an exploratory analysis of the association of aspirin use with mortality stratified by BMI."	3.91	Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Cao, Y; Chan, AT; Loomans-Kropp, HA; Pinsky, P; Umar, A, 2019)
"A murine model of asbestos-induced mesothelioma was used to test this hypothesis by providing the NSAID, aspirin, daily in the feed at 50mg/kg or 250 mg/kg."	3.80	Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort. ( Alfonso, H; Bill Musk, AW; Lake, RA; Nowak, AK; Olsen, N; Robinson, BW; Robinson, C; Woo, S, 2014)
" The effect of aspirin on mediastinal lymph node metastasis of LCC cells from the primary injection sites was then examined."	3.80	Aspirin reduces lung cancer metastasis to regional lymph nodes. ( Amano, H; Hosono, K; Ito, Y; Kitasato, H; Majima, M; Matsui, Y; Ogawa, F; Satoh, Y, 2014)
"From the Swedish Cancer Register, we identified patients diagnosed with colorectal, lung, prostate and breast cancers between 2006 and 2009 and matched them to the Swedish Prescribed Drug Register to obtain information on low-dose aspirin use prior to diagnosis."	3.79	Low-dose aspirin use and cancer characteristics: a population-based cohort study. ( Czene, K; Jonsson, F; Lundholm, C; Pawitan, Y; Smedby, KE; Yin, L, 2013)
"The antiproliferative activity of the aspirin derivative [2-acetoxy-(2-propynyl)benzoate]hexacarbonyldicobalt (Co-ASS) and its analogue hexacarbonyl[μ-(2-ethylphenyl)methanol]dicobalt (Co-EPM) was investigated on malignant pleural mesothelioma (MPM) cell lines, having an epithelioid or a sarcomatoid phenotype."	3.79	The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells. ( Bonarrigo, I; Gabano, E; Gust, R; Osella, D; Ravera, M; Zanellato, I, 2013)
"Long-term use of alternate-day, low-dose aspirin may reduce risk for colorectal cancer in healthy women."	3.79	Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. ( Buring, JE; Cook, NR; Lee, IM; Moorthy, MV; Zhang, SM, 2013)
"To report a case of metastatic leiomyosarcoma, in which a patient developed chest pain accompanied by acute left bundle-branch block (LBBB) after gemcitabine infusion."	3.75	Gemcitabine-induced acute coronary syndrome: a case report. ( Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozdemir, M; Ozturk, B; Sahin, G; Tacoy, G; Topal, S; Yaman, E; Yildiz, R, 2009)
"The association between lung carcinoma risk and regular use of NSAIDs, including aspirin, was evaluated in a hospital-based case-control study of 1038 patients and 1002 controls."	3.72	Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. ( Altorki, NK; Chen, SQ; Citron, M; Muscat, JE; Neugut, AI; Olson, S; Richie, JP; Stellman, SD, 2003)
"A patient who had small cell lung cancer complicated by symmetrical peripheral gangrene, secondary to spontaneous platelet aggregation, improved dramatically after starting aspirin treatment."	3.68	Digital gangrene in small cell lung cancer: response to aspirin treatment. ( Arrowsmith, JE; Bevan, DH; Cummin, AR; Nanson, EM; Woodhead, MA, 1991)
"The frequency of metastases of malignant diethylnitrosamine-induced hepatomas and haemangioendotheliomas of the liver of female Sprague-Dawley rats (29%) was not influenced by application of acetyl-salicylic acid or phenprocoumon."	3.65	[Studies on the influence of anticoagulants on metastase formation of autochthonic hepatomas in the rat (author's transl)]. ( Schmähl, D, 1975)
"Aspirin was not associated with a risk reduction, perhaps due to residual confounding."	2.73	Nonsteroidal anti-inflammatory drugs and risk of lung cancer. ( García Rodríguez, LA; Hernández-Díaz, S, 2007)
"We measured serum levels of soluble (s) P-selectin and thromboxane B2 (TxB2) in patients with lung cancer treated with gefitinib, and investigated the effect of low-dose aspirin on some adverse effects of gefitinib."	2.72	Aspirin reduces adverse effects of gefitinib. ( Kanazawa, S; Kinoshita, Y; Komiyama, Y; Muramatsu, M; Nomura, S; Yamaguchi, K, 2006)
"Prostate cancer was reduced with supplementation among those in the highest BMI quartile (RR = 0."	2.69	Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). ( Buring, JE; Cook, NR; Hennekens, CH; Le, IM; Manson, JE, 2000)
"To complete research in this type of coagulation and cancer, a multicentric randomized clinical trial was performed, including 303 patients with small cell lung cancer (SCLC), treated by the addition of aspirin at 1 g/day (a dosage at which aspirin is considered to be a platelet aggregation inhibitor) to combined chemotherapy."	2.67	No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group. ( Chastang, C; Fabre, C; Lebeau, B; Massin, F; Muir, JF; Vincent, J, 1993)
"Aspirin is a promising agent for chemoprevention of lung cancer."	2.53	Meta-analysis of aspirin use and risk of lung cancer shows notable results. ( Hochmuth, F; Jochem, M; Schlattmann, P, 2016)
"Aspirin has received increasing attention owing to its potential as a chemopreventive agent against lung cancer."	2.47	Aspirin use and risk for lung cancer: a meta-analysis. ( Kwon, HT; Lee, CM; Myung, SK; Oh, SW; Park, JY, 2011)
"Risk of lung cancer was a non-significant 16% lower for regular aspirin users of one or two tablets per week and a significant 55% higher for users of 15 or more tablets per week compared with women who never regularly used aspirin."	2.44	Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency. ( Bain, C; Chan, AT; Colditz, GA; Feskanich, D; Pandeya, N; Speizer, FE, 2007)
"The relative risk of colorectal cancer is about 0."	2.41	Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects. ( Sjödahl, R, 2001)
"Systematic inflammation has been reported to contribute to cancer progression through various mechanisms; however, the exact mechanism is still the subject of research."	1.91	Inhibitory effect of aspirin on inflammation-induced lung metastasis of cancer cells associated with neutrophil infiltration. ( Fukuda, K; Hirahashi, J; Kawakubo, H; Kitagawa, Y; Kobayashi, R; Matsuda, S; Matsui, K; Nakamura, R; Nishimura, E; Okubo, K; Takeuchi, M, 2023)
"Combination therapy has become the hallmark of lung cancer treatment, as it reduces the dosage intensity of individual drugs while increasing their efficacy."	1.72	The combination of decitabine and aspirin inhibits tumor growth and metastasis in non-small cell lung cancer. ( Li, N; Song, B; Xu, M; Yang, X, 2022)
"Aspirin has been reported to promote apoptosis, inhibit proliferation, stemness, angiogenesis, cancer-associated inflammation and migration in NSCLC."	1.72	Aspirin blocks AMPK/SIRT3-mediated glycolysis to inhibit NSCLC cell proliferation. ( Li, G; Ma, Y; Ren, G; Wang, X; Zheng, Z, 2022)
"When aspirin and α-blocker were used simultaneously, it could lower the risk of lung cancer significantly (HR: 0."	1.62	Antihypertensive treatments and risks of lung Cancer: a large population-based cohort study in Hong Kong. ( Lam, ASM; Li, J; Tsoi, KKF; Yau, STY; Yiu, KKL, 2021)
"Aspirin exposure was analyzed to identify a possible association with mortality in patients with inoperable NSCLC."	1.62	The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study. ( Chen, PC; Chuang, MC; Hsieh, MJ; Hung, MS; Lin, YC; Yang, TM; Yang, YH, 2021)
"001) in a dose-response fashion, and these associations were prominent among participants with a metformin cumulative defined daily dose of 547."	1.62	The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data. ( Cho, JH; Cho, M; Jeong, SM; Kang, J; Kim, J; Shin, DW, 2021)
"Osimertinib is the treatment of choice for advanced EGFR-mutant non-small cell lung cancer (NSCLC)."	1.56	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. ( Fang, B; He, Y; Heymach, JV; Hong, L; Hubert, SM; Jack Lee, J; Le, X; Lewis, J; Liu, X; Nilsson, M; Rinsurongkawong, W; Roth, J; Spelman, A; Swisher, S; Wu, S; Zhang, J, 2020)
"Aspirin was able to markedly decrease the expression of PD-L1 at the mRNA and protein levels in lung cancer cells."	1.56	Aspirin-targeted PD-L1 in lung cancer growth inhibition. ( Dong, Y; Lv, C; Yang, Q; Zhang, Y, 2020)
"Lung cancer is the leading cause of cancer death and is commonly treated by cisplatin."	1.56	Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness. ( Hui, Z; Wang, T; Zhao, M, 2020)
"The study aimed to investigate the effect and mechanism of aspirin combined with vinorelbine on the proliferation and apoptosis of non-small cell lung cancer cells."	1.56	[Effect and mechanism of aspirin combined with vinorelbine on non-small cell lung cancer]. ( Cui, L; Liu, Z; Qiu, YN; Teng, YO; Xu, Y; Yu, P, 2020)
" In this work, we reported a novel kind of BiOI@CuS nanoparticle to achieve safe and effective therapy of lung cancer by co-loading hydrochloric acid doxorubicin (DOX) and aspirin phenacetin and caffeine (APC)."	1.51	Construction of DOX/APC co-loaded BiOI@CuS NPs for safe and highly effective CT imaging and chemo-photothermal therapy of lung cancer. ( Cheng, J; He, D; Huang, G; Li, W; Wang, R; Zhang, Y; Zhu, J, 2019)
" Long-term administration of aspirin leads to reduced distant metastases in murine models and clinical trials, but the COX isoform, downstream prostanoid, and cell compartment responsible for this effect are yet to be determined."	1.51	Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. ( Allen, PD; Armstrong, PC; Cerutti, C; Gil-Bernabé, AM; Gomes, AL; Lucotti, S; Markelc, B; Mitchell, JA; Muschel, RJ; Ridley, AJ; Smart, S; Soyer, M; Warner, TD; Watson, K, 2019)
"Despite treatment of lung cancer with radiotherapy and chemotherapy, the survival rate of lung cancer patients remains poor."	1.48	Disruption of Chromosomal Architecture of cox2 Locus Sensitizes Lung Cancer Cells to Radiotherapy. ( Cao, X; Chen, S; Dai, H; Sun, Y; Wang, J; Wu, L; Wu, T; Xu, A; Zhang, Y; Zhao, G, 2018)
" The two NSAIDs proved to be safe and efficacious in the experimental model used."	1.43	Selective inhibition by aspirin and naproxen of mainstream cigarette smoke-induced genotoxicity and lung tumors in female mice. ( Balansky, R; D'Oria, C; De Flora, S; Ganchev, G; Iltcheva, M; La Maestra, S; Micale, RT; Steele, VE, 2016)
"We identified 14,743 individuals with colorectal cancer and 5888 with lung cancer."	1.42	Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis. ( Auer, G; Czene, K; Pawitan, Y; Setiawan, A; Smedby, KE; Yin, L, 2015)
"Accelerated progression of residual hepatocellular carcinoma (HCC) after incomplete radiofrequency ablation (RFA) has been reported more frequently."	1.42	Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation. ( Ding, J; Duan, B; Jiang, T; Lu, S; Zhang, X, 2015)
"Treatment with aspirin suppressed the viability/proliferation of BON1, NCI-H727 and GOT1 cells in a time- and dose-dependent manner."	1.40	Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. ( Auernhammer, CJ; Göke, B; Maurer, J; Spampatti, M; Spöttl, G; Vlotides, G, 2014)
"He had been treated for lung cancer by chemotherapy and irradiation 3 years earlier."	1.40	[Case of cardiac tamponade during the treatment of acute cerebral infarction]. ( Nagasawa, H; Ono, H; Tanaka, H; Yamakawa, T, 2014)
"Aspirin (ASA) is a non-selective cyclooxygenase (COX) inhibitor that contributes to the treatment of inflammatory conditions such as RA."	1.39	Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells. ( Chang, HY; Chang, PY; Chen, TL; Cheng, AL; Chuang, SE; Hsieh, MC; Lai, GM; Lee, LM; Yan, KH; Yan, MD; Yao, CJ, 2013)
"Troglitazone (TGZ) is a synthetic thiazolidinedione drug belonging to a group of potent peroxisome proliferator-activated receptor gamma (PPAR gamma) agonists known to inhibit proliferation, alter cell cycle regulation, and induce apoptosis in various cancer cell types."	1.36	The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. ( Chang, HY; Cheng, AL; Chuang, SE; Lai, GM; Yan, KH; Yao, CJ, 2010)
"Aspirin has been proven to reduce cardiovascular mortality as a secondary prophylactic agent, but not as a primary agent."	1.36	Aspirin and non-small cell lung cancer resections: effect on long-term survival. ( Carr, M; Fontaine, E; McShane, J; Mediratta, N; Page, R; Poullis, M; Shackcloth, M; Soorae, A, 2010)
"Lung cancer is the leading cause of cancer death in the US."	1.35	Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. ( Coogan, P; Kelly, JP; Rosenberg, L; Strom, BL, 2008)
"Baby aspirin and NSAID use was associated with a significant reduction in risk of NSCLC only among 65- to 74-year-olds."	1.35	Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. ( Claeys, GB; Cote, ML; Prysak, G; Schwartz, AG; Van Dyke, AL; Wenzlaff, AS, 2008)
"Lung cancer is the most common cause of cancer death in the United States."	1.34	Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). ( Bepler, G; Gray, J; Kelley, M; Kurie, J; Mao, JT; Szabo, E, 2007)
" Information on dosage and duration of use were not available for this analysis."	1.33	Association between nonsteroidal anti-inflammatory drug use and the incidence of lung cancer in the Iowa women's health study. ( Anderson, KE; Folsom, AR; Hayes, JH, 2006)
"Although no lung metastasis was observed in the rats killed at the end of the period of carcinogen exposure, lung metastasis was found in 100% of animals in all the groups at the end of the experiment."	1.32	Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. ( Futakuchi, M; Ogawa, K; Shirai, T; Takahashi, S; Tamano, S, 2004)
" Although there was no clear evidence of a dose-response relationship, we observed risk reductions associated with greater frequency of use."	1.31	Regular aspirin use and lung cancer risk. ( Bepler, G; Cummings, KM; Falkner, KL; Loewen, GM; Menezes, RJ; Moysich, KB; Reid, ME; Ronsani, A; Swede, H, 2002)
" NNK increased plasma prostaglandin E2 (PGE2) basal levels by 413%, whereas ASA attenuated this elevation in a dose-response manner (r2 = 0."	1.30	Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. ( Castonguay, A; Rioux, N, 1998)
" Animals were treated with a dosage regimen of aspirin which inhibited PES but had no effect on the cytochrome P-450-dependent oxidation of 7,8-dihydrodihydroxybenzo(a)pyrene."	1.27	Effect of aspirin and indomethacin on the formation of benzo(a)pyrene-induced pulmonary adenomas and DNA adducts in A/HeJ mice. ( Adriaenssens, PI; Anderson, MW; Boorman, GA; Eling, TE; Sivarajah, K, 1983)
"Pulmonary metastases with CT26 cells could be inhibited by induction of thrombocytopenia, and reconstituted by infusion of either murine or human platelets."	1.27	Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. ( Ambrogio, C; Coller, BS; Karpatkin, S; Pearlstein, E, 1988)

Timeframe	Studies, this research(%)	All Research%
pre-1990	22 (14.86)	18.7374
1990's	17 (11.49)	18.2507
2000's	32 (21.62)	29.6817
2010's	56 (37.84)	24.3611
2020's	21 (14.19)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Retrospective Epidemiological Study to Map Out Patients With Chronic Obstructive Pulmonary Disease (COPD) and Describe COPD Health Care in Real-Life Primary Care During the First Ten Years of the 21th Century[NCT01146392]		27,394 participants (Actual)	Observational	2010-06-30	Completed
Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479]	Phase 3	39,876 participants (Actual)	Interventional	1992-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	participants (Number)
	Total invasive cancer	Cancer death
Aspirin + Vitamin E	716	152
Aspirin Only	722	132
Both Placebos	706	143
Vitamin E Only	721	156

Intervention	Participants (Number)
	Major cardiovascular event	Stroke	Myocardial infarction	Cardiovascular death
Aspirin + Vitamin E	232	108	102	54
Aspirin Only	245	113	96	66
Both Placebos	272	133	99	74
Vitamin E Only	250	133	94	52

Article	Year
Non-steroidal anti-inflammatory drugs and risk of mortality in lung cancer: A meta-analysis of 5 prospective cohorts studies. Medicine, 2019, Volume: 98, Issue:32 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Lung Neoplasms; Prospective Studies	2019
Reducing Tobacco-Related Disability in Chronic Smokers. The American journal of medicine, 2020, Volume: 133, Issue:8 Topics: Aortic Aneurysm, Abdominal; Aspirin; Cardiovascular Diseases; Cigarette Smoking; Early Detection of	2020
Aspirin use and lung cancer risk: a possible relationship? Evidence from an updated meta-analysis. PloS one, 2015, Volume: 10, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Carcinoma, Non-Small-Cell	2015
Meta-analysis of aspirin use and risk of lung cancer shows notable results. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2016, Volume: 25, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Databases, Factual; Humans;	2016
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The Lancet. Oncology, 2009, Volume: 10, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Digestive	2009
Aspirin use and risk for lung cancer: a meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Female; Huma	2011
Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clinical lung cancer, 2012, Volume: 13, Issue:1 Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Humans; Lung	2012
Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO). Cancer causes & control : CCC, 2011, Volume: 22, Issue:12 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Lung Neoplasms; Male; Middle	2011
Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency. British journal of cancer, 2007, Nov-05, Volume: 97, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ca	2007
Cancer cell damage at the vascular endothelium. Annals of the New York Academy of Sciences, 1983, Volume: 416 Topics: Animals; Aspirin; Blood Vessels; Capillaries; Endothelium; Fibrin; Heparin; Lung Neoplasms; Microcir	1983
[Aspirin against cancer]. La Revue de medecine interne, 2000, Volume: 21 Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Clinical T	2000
Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects. The American journal of medicine, 2001, Jan-08, Volume: 110, Issue:1A Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl	2001
Clinical pharmacological aspects of ascorbic acid. Annals of the New York Academy of Sciences, 1975, Sep-30, Volume: 258 Topics: Administration, Oral; Aged; Antigen-Antibody Reactions; Ascorbic Acid; Aspirin; Child; Common Cold;	1975

aspirin and Lung Neoplasms

Research Excerpts

Research

Studies (148)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer

Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death)

Reviews

Trials

Other Studies

Authors	Studies
Basudhar, D	1
Bharadwaj, G	1
Cheng, RY	1
Jain, S	1
Shi, S	1
Heinecke, JL	1
Holland, RJ	1
Ridnour, LA	1
Caceres, VM	1
Spadari-Bratfisch, RC	1
Paolocci, N	1
Velázquez-Martínez, CA	1
Wink, DA	1
Miranda, KM	1
Li, J	1
Lam, ASM	1
Yau, STY	1
Yiu, KKL	1
Tsoi, KKF	1
Chuang, MC	1
Yang, YH	1
Hsieh, MJ	1
Lin, YC	1
Yang, TM	1
Chen, PC	1
Hung, MS	1
Xu, R	3
Yan, Y	1
Zheng, X	1
Zhang, H	1
Chen, W	1
Li, H	1
Dong, Z	1
Yu, SY	1
Ip, MS	1
Li, X	1
Cheung, KS	1
Ren, QW	1
Wu, MZ	1
Li, HL	1
Wong, PF	1
Tse, HF	1
Yiu, KH	1
Xu, M	1
Song, B	1
Yang, X	1
Li, N	1
Ren, G	1
Ma, Y	1
Wang, X	1
Zheng, Z	1
Li, G	1
Nishimura, E	1
Fukuda, K	1
Matsuda, S	1
Kobayashi, R	1
Matsui, K	1
Takeuchi, M	1
Okubo, K	1
Hirahashi, J	1
Nakamura, R	1
Kawakubo, H	1
Kitagawa, Y	1
Chen, Y	2
Kang, L	2
Zhu, Y	2
Jing, C	1
Zhang, Y	3
Wang, R	3
Li, W	1
Huang, G	1
Zhu, J	1
Cheng, J	1
He, D	1
Khan, P	1
Bhattacharya, A	1
Sengupta, D	1
Banerjee, S	1
Adhikary, A	1
Das, T	1
Loomans-Kropp, HA	1
Pinsky, P	1
Cao, Y	1
Chan, AT	2
Umar, A	1
Han, R	1
Hao, S	1
Lu, C	1
Zhang, C	1
Lin, C	1
Li, L	1
Wang, Y	1
Hu, C	1
He, Y	2
Smeda, M	1
Kij, A	1
Proniewski, B	1
Matyjaszczyk-Gwarda, K	1
Przyborowski, K	1
Jasztal, A	1
Derszniak, K	1
Berkowicz, P	1
Kieronska-Rudek, A	1
Stojak, M	1
Sternak, M	1
Chlopicki, S	1
Lv, C	1
Dong, Y	2
Yang, Q	1
Ambrose, JA	1
Najafi, A	1
Jain, V	1
Muller, JE	1
Ranka, S	1
Barua, RS	1
Chen, J	2
Xia, J	2
Huang, J	3
Kang, J	1
Jeong, SM	1
Shin, DW	1
Cho, M	1
Cho, JH	1
Kim, J	1
Liu, X	1
Hong, L	1
Nilsson, M	1
Hubert, SM	1
Wu, S	1
Rinsurongkawong, W	1
Lewis, J	1
Spelman, A	1
Roth, J	1
Swisher, S	1
Jack Lee, J	1
Fang, B	1
Heymach, JV	1
Zhang, J	1
Le, X	1
Jiang, Y	1
Su, Z	1
Li, C	1
Wen, Y	1
Liang, H	1
He, J	1
Liang, W	1
Zhang, W	1
Xia, L	1
Ren, X	1
Cui, M	1
Liu, T	1
Ling, C	1
Xu, Y	2
Deng, D	1
Zhang, X	2
Gu, Y	1
Wang, P	1
Zhao, M	1
Wang, T	2
Hui, Z	1
Shojaee, S	1
Nana-Sinkam, P	1
Nounu, A	1
Walker, V	1
Richmond, RC	1
Cui, L	1
Qiu, YN	1
Teng, YO	1
Yu, P	1
Liu, Z	1
Braillon, A	1
Zheng, L	1
Jia, J	1
Dai, H	2
Wan, L	1
Liu, J	1
Hu, L	1
Zhou, M	1
Qiu, M	1
Chen, X	1
Chang, L	1
Kim, JY	1
Reckamp, K	1
Raz, DJ	1
Xia, Z	1
Shen, B	1
Ma, R	1
Bi, Y	1
Kou, J	1
Zhou, J	1
Shi, J	1
Sandelin, M	1
Mindus, S	1
Thuresson, M	1
Lisspers, K	1
Ställberg, B	1
Johansson, G	1
Larsson, K	1
Janson, C	1
Song, JM	1
Upadhyaya, P	1
Kassie, F	1
Usman, MW	1
Gao, J	1
Zheng, T	1
Rui, C	1
Li, T	1
Bian, X	1
Cheng, H	1
Liu, P	2
Luo, F	1
Sun, Y	1
Chen, S	1
Wu, T	1
Cao, X	1
Zhao, G	1
Xu, A	1
Wang, J	2
Wu, L	1
Erickson, P	1
Gardner, LD	1
Loffredo, CA	1
St George, DM	1
Bowman, ED	1
Deepak, J	1
Mitchell, K	1
Meaney, CL	1
Langenberg, P	1
Bernat, DH	1
Amr, S	1
Ryan, BM	1
Mormile, R	1
Stamenovic, D	1
Schneider, T	1
Messerschmidt, A	1
Gong, L	1
Zhang, D	1
Lei, Y	1
Qian, Y	1
Tan, X	1
Han, S	1
Gan, H	1
Lin, L	1
Hu, N	1
Yang, Y	1
Gao, Y	1
Pei, Y	1
Chen, K	1
Sun, B	1
Ye, S	1
Lee, M	1
Lee, D	1
Ha, EH	1
Chun, EM	2
Su, B	1
Wang, S	1
Lucotti, S	1
Cerutti, C	1
Soyer, M	1
Gil-Bernabé, AM	1
Gomes, AL	1
Allen, PD	1
Smart, S	1
Markelc, B	1
Watson, K	1
Armstrong, PC	1
Mitchell, JA	1
Warner, TD	1
Ridley, AJ	1
Muschel, RJ	1
Martin-Martin, A	1
Rivera-Dictter, A	1
Muñoz-Uribe, M	1
López-Contreras, F	1
Pérez-Laines, J	1
Molina-Berríos, A	1
López-Muñoz, R	1
Yan, KH	2
Lee, LM	1
Hsieh, MC	1
Yan, MD	1
Yao, CJ	2
Chang, PY	1
Chen, TL	1
Chang, HY	2
Cheng, AL	2
Lai, GM	2
Chuang, SE	2
Cook, NR	2
Lee, IM	1
Zhang, SM	1
Moorthy, MV	1
Buring, JE	2
Jonsson, F	1
Yin, L	2
Lundholm, C	1
Smedby, KE	2
Czene, K	2
Pawitan, Y	2
Zanellato, I	1
Bonarrigo, I	1
Ravera, M	1
Gabano, E	1
Gust, R	1
Osella, D	1
Brucculeri, F	1
Oppezzo, E	1
Taverna, GG	1
Dell'era, G	1
Demarchi, PG	1
Taverna, G	1
Mercogliano, D	1
Barbero, S	1
Pommergaard, HC	1
Burcharth, J	1
Rosenberg, J	1
Raskov, H	1
Ogawa, F	1
Amano, H	1
Ito, Y	1
Matsui, Y	1
Hosono, K	1
Kitasato, H	1
Satoh, Y	1
Majima, M	1
Kanzaki, R	1
Inoue, M	1
Minami, M	1
Shintani, Y	1
Nakagiri, T	1
Funaki, S	1
Sawabata, N	1
Okumura, M	1
Nagasawa, H	1
Ono, H	1
Tanaka, H	1
Yamakawa, T	1
Spampatti, M	1
Vlotides, G	1
Spöttl, G	1
Maurer, J	1
Göke, B	1
Auernhammer, CJ	1
Robinson, C	1
Alfonso, H	1
Woo, S	1
Olsen, N	1
Bill Musk, AW	1
Robinson, BW	1
Nowak, AK	1
Lake, RA	1
Baik, CS	1
Brasky, TM	1
Pettinger, M	1
Luo, J	1
Gong, Z	1
Wactawski-Wende, J	1
Prentice, RL	1
Harris, K	1
Kebbe, J	1
Lang Kuhs, KA	1
Hildesheim, A	1
Trabert, B	1
Kemp, TJ	1
Purdue, MP	1
Wentzensen, N	1
Katki, HA	1
Pinto, LA	1
Loftfield, E	1
Safaeian, M	1
Chaturvedi, AK	1
Shiels, MS	1
Setiawan, A	1
Auer, G	1
Maki, M	1
Tsubochi, H	1
Endo, T	1
Endo, S	1
Jiang, HY	1
Huang, TB	1
Xu, L	1
Yu, J	1
Wu, Y	1
Geng, J	1
Yao, XD	1
Hochmuth, F	1
Jochem, M	1
Schlattmann, P	1
Yang, H	1
Pellegrini, L	1
Napolitano, A	1
Giorgi, C	1
Jube, S	1
Preti, A	1
Jennings, CJ	1
De Marchis, F	1
Flores, EG	1
Larson, D	1
Pagano, I	1
Tanji, M	1
Powers, A	1
Kanodia, S	1
Gaudino, G	1
Pastorino, S	1
Pass, HI	1
Pinton, P	1
Bianchi, ME	1
Carbone, M	1
Balansky, R	2
Ganchev, G	1
Iltcheva, M	1
Micale, RT	2
La Maestra, S	2
D'Oria, C	1
Steele, VE	2
De Flora, S	2
D'Agostini, F	1
Izzotti, A	1
Mastracci, L	1
Camoirano, A	1
Trosko, JE	1
Mc Menamin, ÚC	1
Cardwell, CR	1
Hughes, CM	1
Murray, LM	1
Jiang, T	1
Ding, J	1
Duan, B	1
Lu, S	1
Maddison, P	1
Veeraputhiran, M	1
Sundermeyer, M	1
Ochmański, W	1
Ozturk, B	1
Tacoy, G	1
Coskun, U	1
Yaman, E	1
Sahin, G	1
Buyukberber, S	1
Yildiz, R	1
Kaya, AO	1
Topal, S	1
Ozdemir, M	1
Benekli, M	1
Kanazawa, S	2
Yamaguchi, K	2
Kinoshita, Y	2
Siomi, K	1
Tujimoto, M	1
Hanayama, K	1
Sasada, S	1
Hirashima, T	1
Imamura, F	1
Nomura, S	2
Cuzick, J	1
Otto, F	1
Baron, JA	2
Brown, PH	1
Burn, J	1
Greenwald, P	1
Jankowski, J	1
La Vecchia, C	1
Meyskens, F	1
Senn, HJ	1
Thun, M	1
Fontaine, E	1
McShane, J	1
Page, R	1
Shackcloth, M	1
Mediratta, N	1
Carr, M	1
Soorae, A	1
Poullis, M	1
Chiaviello, A	1
Paciello, I	1
Postiglione, I	1
Crescenzi, E	1
Palumbo, G	1
Oh, SW	1
Myung, SK	1
Park, JY	1
Lee, CM	1
Kwon, HT	1
Xu, J	1
Yin, Z	1
Gao, W	1
Liu, L	1
Huang, P	1
Yin, Y	1
Yu, R	1
Shu, Y	1
Kato, T	1
Fujino, H	1
Oyama, S	1
Kawashima, T	1
Murayama, T	1
McCormack, VA	1
Hung, RJ	1
Brenner, DR	1
Bickeböller, H	1
Rosenberger, A	1
Muscat, JE	2
Lazarus, P	1
Tjønneland, A	1
Friis, S	1
Christiani, DC	1
Le Marchand, L	1
Rennert, G	1
Rennert, HS	1
Andrew, AS	1
Orlow, I	1
Park, B	1
Boffetta, P	1
Duell, EJ	1
Antonoff, MB	1
D'Cunha, J	1
Lim, WY	1
Chuah, KL	1
Eng, P	1
Leong, SS	1
Lim, E	1
Lim, TK	1
Ng, A	1
Poh, WT	1
Tee, A	1
Teh, M	1
Salim, A	1
Seow, A	1
Bausili, M	1
Abreu, S	1
Unzueta, MC	1
García Álvarez, M	1
Crespí, J	1
Moral, MV	1
Huang, Y	1
Serebruany, VL	1
Dinicolantonio, JJ	1
Can, MM	1
Goto, S	1
Futakuchi, M	2
Ogawa, K	2
Sano, M	1
Tamano, S	2
Takeshita, F	1
Shirai, T	2
Liu, LT	1
Chang, HC	1
Chiang, LC	1
Hung, WC	1
Moysich, KB	1
Menezes, RJ	1
Ronsani, A	1
Swede, H	1
Reid, ME	1
Cummings, KM	1
Falkner, KL	1
Loewen, GM	1
Bepler, G	2
Chen, SQ	1
Richie, JP	1
Altorki, NK	1
Citron, M	1
Olson, S	1
Neugut, AI	1
Stellman, SD	1
Holick, CN	1
Michaud, DS	1
Leitzmann, MF	1
Willett, WC	1
Giovannucci, E	1
Takahashi, S	1
Muramatsu, M	1
Komiyama, Y	1
Duan, W	1
Zhang, L	1
Hayes, JH	1
Anderson, KE	1
Folsom, AR	1
Hernández-Díaz, S	1
García Rodríguez, LA	1
Gradilone, A	1
Silvestri, I	1
Scarpa, S	1
Morrone, S	1
Gandini, O	1
Pulcinelli, FM	1
Gianni, W	1
Frati, L	1
Aglianò, AM	1
Gazzaniga, P	1
Kunita, A	1
Kashima, TG	1
Morishita, Y	1
Fukayama, M	1
Kato, Y	1
Tsuruo, T	1
Fujita, N	1
Ye, B	1
Zhang, YX	1
Yang, F	1
Chen, HL	1
Xia, D	1
Liu, MQ	1
Lai, BT	1
Harris, RE	1
Beebe-Donk, J	1
Alshafie, GA	1
Gray, J	1
Mao, JT	1
Szabo, E	1
Kelley, M	1
Kurie, J	1
Feskanich, D	1
Bain, C	1
Pandeya, N	1
Speizer, FE	1
Colditz, GA	1
Kelly, JP	1
Coogan, P	1
Strom, BL	1
Rosenberg, L	1
Van Dyke, AL	1
Cote, ML	1
Prysak, G	1
Claeys, GB	1
Wenzlaff, AS	1
Schwartz, AG	1
Zhukovskaia, ES	1
Orlova, PN	1
Madzhuga, AV	1
Kishnareva, NI	1
Adriaenssens, PI	1
Sivarajah, K	1
Boorman, GA	1
Eling, TE	1
Anderson, MW	1
Weiss, L	1
Glaves, D	1
Starczewski, M	1
Voigtmann, R	1
Peskar, BA	1
Peskar, BM	1
Diamond, GA	1
Forrester, JS	1
Gunby, P	1
Nelson, C	1
Adami, HO	1
Schreinemachers, DM	1
Everson, RB	1
Brown, DC	1
Purushotham, AD	1
George, WD	1
Lebeau, B	2
Chastang, C	2
Muir, JF	1
Vincent, J	1
Massin, F	1
Fabre, C	1
Brawley, OW	1
Phillips, PH	1
Cheson, BD	1
Clària, J	1
Lee, MH	1
Serhan, CN	1
Iigo, M	1
Nakagawa, T	1
Ishikawa, C	1
Iwahori, Y	1
Asamoto, M	1
Yazawa, K	1
Araki, E	1
Tsuda, H	1
Duperron, C	1
Castonguay, A	4
Rioux, N	3
Liede, KE	1
Haukka, JK	1
Saxén, LM	1
Heinonen, OP	1
El-Bayoumy, K	1
Iatropoulos, M	1
Amin, S	1
Hoffmann, D	1
Wynder, EL	1
Witschi, H	3
Espiritu, I	2
Uyeminami, D	1
Gu, Z	1
Qiu, W	1
He, R	1
Zhang, Z	1
Zhou, X	1
Mabro, M	1
de Gramont, A	1
Le, IM	1
Manson, JE	1
Hennekens, CH	1
Sjödahl, R	1
Yao, R	1
You, M	1
Bauer, AK	1
Dwyer-Nield, LD	1
Hankin, JA	1
Murphy, RC	1
Malkinson, AM	1
Suffia, M	1
Pinkerton, KE	1
Karna, E	1
Pałka, JA	1
Akhmedkhanov, A	1
Toniolo, P	1
Zeleniuch-Jacquotte, A	1
Koenig, KL	1
Shore, RE	1
Hilgard, P	2
Heller, H	1
Schmidt, CG	1
Carmel, RJ	1
Brown, JM	1
Schmähl, D	1
Pollard, M	1
Chang, CF	1
Luckert, PH	1
Cattan, A	1
Pourny, C	1
Carpentier, Y	1
Cattan, E	1
Barouh, M	1
Wilson, CW	1
Arrowsmith, JE	1
Woodhead, MA	1
Bevan, DH	1
Nanson, EM	1
Cummin, AR	1
Talmadge, JE	1
Bowersox, O	1
Tribble, H	1
Shepard, M	1
Liggitt, D	1
Bastida, E	1
Almirall, L	1
Ordinas, A	1
Lau, SS	1
McMahon, JB	1
McMenamin, MG	1
Schuller, HM	1
Boyd, MR	1
Karpatkin, S	1
Pearlstein, E	1
Ambrogio, C	1
Coller, BS	1
Hindman, BJ	1
Koka, BV	1
Benichou, J	1
Kolenich, JJ	1
Mansour, EG	1
Flynn, A	1
Wood, S	1
Gasic, GJ	1
Gasic, TB	1
Galanti, N	1
Johnson, T	1
Murphy, S	1

Article	Year
Nonsteroidal Anti-Inflammatory Drug and Aspirin Use in Relation to Lung Cancer Risk among Postmenopausal Women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015, Volume: 24, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Incidence; Lung Neoplasms; M	2015
Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015, Volume: 24, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Colorectal Neoplasms; Early Dete	2015
[Influence of antiplatelet drugs (AD) on the efectiveness of combined therapy in patients with small cell lung cancer. Part I. Influence of AD on the haemostatic system]. Przeglad lekarski, 2008, Volume: 65, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Blood Coagulation; Carcinoma,	2008
Aspirin reduces adverse effects of gefitinib. Anti-cancer drugs, 2006, Volume: 17, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspi	2006
Nonsteroidal anti-inflammatory drugs and risk of lung cancer. International journal of cancer, 2007, Apr-01, Volume: 120, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi	2007
Coming: a 'Dear Doctor' letter that you may want to ponder. JAMA, 1982, Mar-12, Volume: 247, Issue:10 Topics: Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Clinical Trials as Topic; Double-Blind	1982
No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group. Cancer, 1993, Mar-01, Volume: 71, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Small Cell; Cycloph	1993
Increased tendency towards gingival bleeding caused by joint effect of alpha-tocopherol supplementation and acetylsalicylic acid. Annals of medicine, 1998, Volume: 30, Issue:6 Topics: Aged; Aspirin; beta Carotene; Humans; Lung Neoplasms; Male; Middle Aged; Periodontal Index; Platelet	1998
Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer causes & control : CCC, 2000, Volume: 11, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Co	2000
[Global approach to the treatment of small cell bronchial cancers]. Bulletin du cancer, 1987, Volume: 74, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma,	1987